Skip to content
Menu

Omeros Corporation OMER

Full chart Compare
Set alert

Price alert · OMER

All alert types
13.21 USD -0.80 (-5.71%)

Regular-session close

13.21 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

13.07 Day range 13.88
8.23 52-week range 21.05
YTD
-23.11%
1 year
+60.51%

5D -3.23 (-18.17%)

141618ThuFriMonTueWed14.55
Market cap
983.66M
Revenue (ttm)
74.36M
Profit margin
132.32%
EPS (ttm)
0.83
Shares out
74.46M
P/E ratio
15.92
Forward P/E
12.68
YTD return
-23.11%
1-year return
+60.51%
50-day average
18.02
Volume
2.02M
Avg volume
1.37M
Open
13.78
Previous close
14.01
Day's range
13.07 – 13.88
52-week range
8.23 – 21.05
Beta
2.99
Analysts
Buy
Price target
27.50 (+108.2%)
Earnings date
Mar 30, 2027

Key statistics

200-day average
13.82
Enterprise value
1.18B
PEG ratio
0.81
Price / sales
14.03
Free cash flow
192.61M
Total cash
95.25M
Total debt
193.80M
Short % of float
17.91%

Fundamental scorecard

6 of 25 checks passed on OMER’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
OMER Revenue — quarterly 35.93M
OMER Net income — quarterly -57.36M
OMER EPS — quarterly -0.79

Earnings

OMER recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 30, 2027Mar 30, 2027-0.09———
Nov 16, 2026Sep 30, 20260.020.06+0.04+200.00%
Aug 13, 2026Jun 30, 2026-0.26830.15+0.42+155.91%
May 13, 2026Mar 31, 2026-0.40-0.24+0.16+40.00%
Mar 31, 2026Dec 31, 2025-0.553.14+3.69+670.91%
Nov 13, 2025Sep 30, 2025-0.58-0.47+0.11+18.97%

Upgrades / downgrades

OMER analyst upgrades and downgrades
DateFirmActionFromTo
Nov 17, 2026HC Wainwright & Co.reitBuyBuy
Oct 14, 2026Cantor FitzgeraldreitOverweightOverweight
Sep 22, 2026Cantor FitzgeraldupNeutralOverweight
Jun 26, 2026HC Wainwright & Co.mainBuyBuy
Jun 10, 2026HC Wainwright & Co.reitBuyBuy
May 14, 2026HC Wainwright & Co.reitBuyBuy

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
omeros.com

News

Your note

Sign in to keep a note on OMER — it syncs with the Stock Master app.

Insider holders

OMER insider holders
InsiderRelationLatest transactionDateShares held
BORGES DAVID J.OfficerSaleSep 22, 20260
CABLE THOMAS JDirectorSaleAug 19, 202635,067
CANCELMO PETER B.General CounselSaleAug 30, 2026200
DEMOPULOS GREGORY A. M.D.Chief Executive OfficerConversion of Exercise of derivative securityFeb 17, 20262,193,250
HANISH ARNOLD CDirectorSaleAug 26, 202612,400

Institution ownership

OMER institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.35%6,046,10184.71MSep 29, 2026
Ingalls & Snyder LLC4.28%3,095,32343.37MSep 29, 2026
Vanguard Capital Management LLC4.22%3,058,09642.84MSep 29, 2026
UBS Group AG4.10%2,970,10741.61MSep 29, 2026
State Street Corporation3.10%2,240,90631.40MSep 29, 2026
Geode Capital Management, LLC2.62%1,895,96126.56MSep 29, 2026

Fund ownership

OMER fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%2,172,33630.43MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.58%1,867,15326.16MSep 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco Biotechnology & Genome ETF1.28%929,58513.02MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.15%831,21811.65MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.09%789,89811.07MAug 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF0.74%533,7507.48MSep 29, 2026